Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655175 | 0.85 | SLC6A3 (0.54) | CYP1A2HSP90AA1HSP90AB1MLYCDSLC6A3 | |
| SCHEMBL4097869 | 0.82 | MLYCD (0.45) | CYP1A2HSP90AA1HSP90AB1MLYCDSLC6A3 | |
| SCHEMBL13664923 | 0.82 | CYP1A2 (0.45) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL13724877 | 0.82 | MLYCD (0.45) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL2128629 | 0.82 | HTR1A (0.53) | — | |
| SCHEMBL6988786 | 0.81 | MLYCD (0.44) | CYP1A2HSP90AA1HSP90AB1MLYCDSLC6A3 | |
| SCHEMBL185480 | 0.81 | MEN1 (0.48) | CYP1A2HSP90AA1HSP90AB1MLYCDSLC6A3 | |
| SCHEMBL4568348 | 0.81 | MLYCD (0.48) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL31346684 | 0.79 | MEN1 (0.49) | CYP1A2CYP3A4CYP2C9CA12CA1 | |
| SCHEMBL27456578 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| US-10336775-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-3186243-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1232153-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| EP-1263753-B1 | IMIDAZOL DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1261602-B1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-14 | — | — | US | disclosed |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | GAIBA ALESSANDRA (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | RAF1, BRAF, ARAF | CYP1A2 1561/4885HSP90AA1 1236/4885HSP90AB1 1040/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | CYP1A2 1969/4885HSP90AA1 2503/4885HSP90AB1 1624/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CYP1A2 1969/4885HSP90AA1 2503/4885HSP90AB1 1624/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | CYP1A2 1969/4885HSP90AA1 2503/4885HSP90AB1 1624/4885 |
| US-10336775-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CYP1A2 1969/4885HSP90AA1 2503/4885HSP90AB1 1624/4885 |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | CYP1A2 3/4885HSP90AA1 1670/4885HSP90AB1 1247/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | CYP1A2 2/4885HSP90AA1 1627/4885HSP90AB1 1237/4885 |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | CYP1A2 1233/4885HSP90AA1 1344/4885HSP90AB1 1197/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CYP1A2 1969/4885HSP90AA1 2503/4885HSP90AB1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.